Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 24,992 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng sold 24,992 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $31.14, for a total value of $778,250.88. Following the transaction, the chief executive officer now owns 605,417 shares in the company, valued at $18,852,685.38. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Andrew Cheng also recently made the following trade(s):

• On Friday, October 18th, Andrew Cheng sold 63,539 shares of Akero Therapeutics stock. The shares were sold at an average price of $31.53, for a total value of $2,003,384.67.
• On Tuesday, September 10th, Andrew Cheng sold 1,738 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.18, for a total transaction of $45,500.84.

Akero Therapeutics Price Performance

Shares of NASDAQ AKRO opened at $31.23 on Friday. The stock has a fifty day moving average price of $27.36 and a 200 day moving average price of $24.24. Akero Therapeutics, Inc. has a 1-year low of $11.25 and a 1-year high of $37.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.89 and a quick ratio of 24.89. The company has a market cap of $2.16 billion, a PE ratio of -9.76 and a beta of -0.25.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. Sell-side analysts forecast that Akero Therapeutics, Inc. will post -3.64 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Akero Therapeutics in a research note on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.20.

Hedge Funds Weigh In On Akero Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. increased its holdings in Akero Therapeutics by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock valued at $156,000 after buying an additional 1,030 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Akero Therapeutics by 2,366.0% in the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock valued at $31,000 after purchasing an additional 1,183 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Akero Therapeutics by 15.6% during the first quarter. Principal Financial Group Inc. now owns 13,766 shares of the company’s stock worth $348,000 after purchasing an additional 1,858 shares during the last quarter. Handelsbanken Fonder AB boosted its position in Akero Therapeutics by 12.4% during the third quarter. Handelsbanken Fonder AB now owns 20,000 shares of the company’s stock worth $574,000 after purchasing an additional 2,200 shares in the last quarter. Finally, ProShare Advisors LLC grew its holdings in Akero Therapeutics by 24.4% in the first quarter. ProShare Advisors LLC now owns 15,001 shares of the company’s stock valued at $379,000 after purchasing an additional 2,945 shares during the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.